Kennedy B P, Soravia C, Moffat J, Xia L, Hiruki T, Collins S, Gallinger S, Bapat B
Department of Biochemistry and Molecular Biology, Merck Frosst Center for Therapeutic Research, Pointe Claire-Dorval, Quebec, Canada.
Cancer Res. 1998 Feb 1;58(3):500-3.
The synovial fluid or group II secretory phospholipase A2 (sPLA2) has been implicated in various inflammatory processes and has been shown to release arachidonic acid for prostaglandin biosynthesis. In human colorectal cancer, both arachidonic acid and eicosanoid levels are elevated. Recently, sPLA2 has been identified as a candidate gene that modifies the Apc gene in the Min mouse, a murine model for familial adenomatous polyposis (FAP). Loss of sPLA2 gene function results in susceptibility to the Min phenotype and the formation of multiple intestinal polyps, whereas mice expressing an active sPLA2 gene are resistant to polyp formation. Therefore, there are two potentially contrasting roles for sPLA2 in colon cancer; one is protection against polyp formation, and the other, the release of arachidonic acid for prostaglandin production and subsequent tumor promotion. To investigate these contrasting dual roles of sPLA2, we have examined the expression and sequence of the sPLA2 mRNA in normal mucosa and duodenal and colorectal polyps from FAP patients. In 11 of 14 patients, there was a significant increase in sPLA2 mRNA levels in the adenoma over the normal tissue. In some cases, there was over 100-fold increase in mRNA levels in the adenoma compared with normal tissue. Analysis of multiple adenomatous polyps from individual patients revealed that not all polyps contained elevated levels of sPLA2 mRNA. Immunoblot analysis also showed that sPLA2 protein expression was elevated in adenoma over normal tissue in five of six FAP patients analyzed. Furthermore, sequence analysis of sPLA2 mRNA present in these samples did not reveal mutations in the coding region. The implications of the up-regulation of sPLA2 in FAP is not clear, but unlike the Min mouse model, it does not seem to have a significant effect on polyp formation. In contrast, the high level of sPLA2 expression is more likely contributing to the elevated levels of arachidonic acid found in colorectal cancer and, in conjunction with the elevated expression of cyclooxygenase-2, could be another factor in tumor formation.
滑膜液或II型分泌性磷脂酶A2(sPLA2)与多种炎症过程有关,并且已被证明可释放花生四烯酸用于前列腺素的生物合成。在人类结直肠癌中,花生四烯酸和类花生酸水平均升高。最近,sPLA2已被鉴定为一种候选基因,它可修饰Min小鼠中的Apc基因,Min小鼠是家族性腺瘤性息肉病(FAP)的小鼠模型。sPLA2基因功能的丧失导致对Min表型的易感性和多个肠息肉的形成,而表达活性sPLA2基因的小鼠对息肉形成具有抗性。因此,sPLA2在结肠癌中可能有两种相互矛盾的作用;一种是防止息肉形成,另一种是释放花生四烯酸用于前列腺素的产生以及随后的肿瘤促进。为了研究sPLA2的这些相互矛盾的双重作用,我们检测了FAP患者正常黏膜、十二指肠和结肠息肉中sPLA2 mRNA的表达和序列。在14例患者中的11例中,腺瘤中sPLA2 mRNA水平比正常组织有显著增加。在某些情况下,腺瘤中的mRNA水平与正常组织相比增加了100倍以上。对个体患者的多个腺瘤性息肉进行分析发现,并非所有息肉都含有升高水平的sPLA2 mRNA。免疫印迹分析还显示,在分析的6例FAP患者中的5例中,腺瘤中sPLA2蛋白表达比正常组织升高。此外,这些样品中存在的sPLA2 mRNA的序列分析未发现编码区的突变。sPLA2在FAP中上调的意义尚不清楚,但与Min小鼠模型不同,它似乎对息肉形成没有显著影响。相反,sPLA2的高表达水平更可能导致结直肠癌中发现的花生四烯酸水平升高,并且与环氧合酶-2的高表达一起,可能是肿瘤形成的另一个因素。